BioCentury
ARTICLE | Company News

Savient, Teva deal

October 6, 2003 7:00 AM UTC

Specialty pharma company SVNT said it is in talks to be acquired by TEVA for a cash sum that approximates SVNT's Oct. 2 close of $6.14. This would value SVNT (formerly Bio-Technology General) at $365....